ArticleGeneral psychiatry2025
Brain network predictors of changes in symptoms and serum BDNF following antidepressant treatment with escitalopram and Yueju Pill in major depressive disorder: a randomised, double-blind, placebo-controlled pilot study.
Article in General psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Yueju Pill, a classic traditional Chinese medicine, shows antidepressant effects rapidly. However, biomarkers that can predict its treatment outcomes in major depressive disorder (MDD) are still lacking. Multimodal magnetic resonance imaging (MRI) offers a promising avenue to identify such biomarkers. Aims: This pilot study aimed to explore whether therapeutic responses to Yueju Pill could be predicted by MRI-derived brain networks and to identify drug-specific biomarkers in comparison to escitalopram, a mainstream antidepressant. Methods: We collected multimodal MRI data and blood samples from 28 outpatients with MDD from the Fourth People's Hospital of Taizhou, who were randomly divided into two groups to receive either Yueju Pill (23 g/time/day) or escitalopram (10 mg, two times a day) for 4 days. Morphological and functional brain networks were constructed and used to predict individual changes in symptoms quantified by the 24-item Hamilton Depression Scale (HAMD-24) scores and serum brain-derived neurotrophic factor (BDNF) levels. Results: After the treatment, both groups exhibited significant reductions in the HAMD-24 scores, while only the Yueju Pill group showed significant increases in the BDNF levels. Gyrification Index-based morphological networks predicted change rates of the HAMD-24 scores in both groups, but sulcus depth-based and cortical thickness-based morphological networks predicted change rates of the HAMD-24 scores and BDNF levels, respectively, only in the Yueju Pill group. Subnetwork analyses revealed that the visual network independently predicted the changes in both the HAMD-24 scores (sulcus depth-based networks) and BDNF levels (cortical thickness-based networks) following Yueju Pill treatment. Conclusions: Morphological but not functional brain networks can predict symptom improvement and BDNF changes of patients with MDD after Yueju Pill treatment. Sulcus depth-based and cortical thickness-based morphological brain networks, particularly their visual subnetworks, might serve as Yueju Pill-specific biomarkers for predicting the therapeutic responses. These findings have the potential to guide personalised therapy for patients with MDD early in the therapeutic process. Trial registration number: ChiCTR1900021114.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.